Literature DB >> 15939315

Bleomycin lung toxicity: who are the patients with increased risk?

E Azambuja1, J F Fleck, R G Batista, S S Menna Barreto.   

Abstract

Bleomycin is an antibiotic drug with anticancer properties produced by Streptomyces verticillus [Cheson BD. Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents. In De Vita Jr. VT, Hellmann S, Rosenberg AS, editors. Cancer principles and practice of oncology. Lippincott Willians & Wilkins; 2001. p. 452-459]. It was isolated in 1966 by Umezawa et al. and its mechanism of action is breaking the DNA double helix by the production of free radicals, which is oxygen and iron dependent [Cheson BD. Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents. In De Vita Jr. VT, Hellmann S, Rosenberg AS, editors. Cancer principles and practice of oncology. Lippincott Willians & Wilkins; 2001. p. 452-459; Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991;65:81-94]. Bleomycin may be inactivated by bleomycin hidrolase presents in normal and tumoral cells [Cheson BD. Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents. In De Vita Jr. VT, Hellmann S, Rosenberg AS, editors. Cancer principles and practice of oncology. Lippincott Willians & Wilkins; 2001. p. 452-459; Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991;65:81-94; Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clinics Chest Med 1990;11:1-20]. The complex bleomycin-Fe has been the most studied because bleomycin joins the DNA and Fe at the same time, and release of free radicals happens in the presence of molecular oxygen [Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991;65:81-94]. Bleomycin has a renal metabolism with 50% of dose eliminated in 4h after its administration and 70% in the next 24h. Its half-life (T 1/2) is not altered, although the creatinine clearance drops to 25-35 ml/min [Cheson BD. Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents. In De Vita Jr. VT, Hellmann S, Rosenberg AS, editors. Cancer principles and practice of oncology. Lippincott Willians & Wilkins; 2001. p. 452-459; Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991;65:81-94]. This drug has been used as cytostatic treatment of many malignant tumors, such as germ cell tumors, lymphomas, head and neck, and Kaposi's sarcomas [Chen XL, Li WB, Zhou AM et al. Role of endogenous peroxynitrite in pulmonary injury and fibrosis induced by bleomycin A5 in rats. Acta Pharmacol Sin 2003;24:697-702]. Minor important adverse effects are myelossupression, nauseas, vomiting, allergic reactions, mucositis, alopecia, erythema, hyperkeratosis, hypopigmentation, skin ulceration, and acute arthritis [Cheson BD. Pharmacology of cancer chemotherapy: miscellaneous chemotherapeutic agents. In De Vita Jr. VT, Hellmann S, Rosenberg AS, editors. Cancer principles and practice of oncology. Lippincott Willians & Wilkins; 2001. p. 452-459; Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991;65:81-94]. Fever is reported in 20-50% of patients and some of them present hyperthermia [Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991;65:81-94].

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939315     DOI: 10.1016/j.pupt.2005.01.007

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  29 in total

Review 1.  Recent progress in histochemistry and cell biology.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2012-02-25       Impact factor: 4.304

Review 2.  Current Treatment Options for Older Patients with Hodgkin Lymphoma.

Authors:  Jordan Carter; Kevin A David; Athena Kritharis; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

3.  Thirdhand Smoke: New Evidence, Challenges, and Future Directions.

Authors:  Peyton Jacob; Neal L Benowitz; Hugo Destaillats; Lara Gundel; Bo Hang; Manuela Martins-Green; Georg E Matt; Penelope J E Quintana; Jonathan M Samet; Suzaynn F Schick; Prue Talbot; Noel J Aquilina; Melbourne F Hovell; Jian-Hua Mao; Todd P Whitehead
Journal:  Chem Res Toxicol       Date:  2016-12-21       Impact factor: 3.739

4.  Disease characteristics and survival outcomes of extragonadal primary germ cell tumour in two Canadian tertiary cancer centres.

Authors:  Jenny J Ko; Tehmina Asif; Haocheng Li; Nimira Alimohamed; Phuong Thao Nguyen; Daniel Y C Heng
Journal:  Can Urol Assoc J       Date:  2016-05-12       Impact factor: 1.862

5.  Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016.

Authors:  Graça M Dores; Rochelle E Curtis; Nicole H Dalal; Martha S Linet; Lindsay M Morton
Journal:  J Clin Oncol       Date:  2020-09-18       Impact factor: 44.544

6.  Pulmonary toxicity after a quick course of combinatorial vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy in cervical cancer.

Authors:  Kyung-Do Ki; Jong-Min Lee; Seon-Kyung Lee; Seo-Yun Tong; Chu-Yeop Huh; Jung-Kyu Ryu; Kyo-Young Kim
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

7.  Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.

Authors:  H Kaiserová; G J M den Hartog; T Simůnek; L Schröterová; E Kvasnicková; A Bast
Journal:  Br J Pharmacol       Date:  2006-10-09       Impact factor: 8.739

8.  Management of older Hodgkin lymphoma patients.

Authors:  Andrew M Evens; Jordan Carter; Kah Poh Loh; Kevin A David
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

9.  History of cancer and mortality in community-dwelling older adults.

Authors:  Elizabeth Kvale; O James Ekundayo; Yan Zhang; Shamima Akhter; Inmaculada Aban; Thomas E Love; Christine Ritchie; Ali Ahmed
Journal:  Cancer Epidemiol       Date:  2010-08-13       Impact factor: 2.984

10.  The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.

Authors:  Andrew M Evens; Fangxin Hong; Leo I Gordon; Richard I Fisher; Nancy L Bartlett; Joseph M Connors; Randy D Gascoyne; Henry Wagner; Mary Gospodarowicz; Bruce D Cheson; Patrick J Stiff; Ranjana Advani; Thomas P Miller; Richard T Hoppe; Brad S Kahl; Sandra J Horning
Journal:  Br J Haematol       Date:  2013-01-29       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.